Patient characteristics, GVHD features, and response to imatinib (N = 39)
| . | Values . |
|---|---|
| Sex ratio, male/female, n | 31/8 |
| Mean age, y (range) | 42 (5-70) |
| Diagnosis, n | |
| AML/ALL | 10/8 |
| MM/CML | 7/4 |
| Other MPS/MDS | 3/2 |
| HD/NHL | 2/3 |
| Type of transplantation, sibling/MUD, n | 23/16 |
| Stem cell source, PBSC/BM, n | 32/7 |
| Conditioning, MA/NMA/RIC, n | 27/1/11 |
| GVHD prophylaxis, n | |
| MTX + CsA/MMF + CsA/CsA | 27/11/1 |
| Acute GVHD target organs, n | |
| Skin/gut/both/none | 26/5/6/2 |
| cGVHD target sites, n (%) | |
| Skin (fibrotic features) | 39 (100) |
| Eye and/or mouth mucosa | 32 (82) |
| Lung (bronchiolitis obliterans) | 18 (46) |
| Liver | 9 (23) |
| Digestive tract | 6 (15) |
| 2 or more target sites | 25 (64) |
| cGVHD skin scoring, n (%) | |
| Grade 3 (> 50% BSA OR deep sclerotic features OR ulcerations OR inability to move) | 33 (85) |
| Grade 2 (< 50% BSA and/or superficial sclerotic features only) | 6 (15) |
| Previous treatments for cGVHD, n (%) | |
| Systemic corticosteroids | 39 (100) |
| MMF | 30 (77) |
| CsA | 24 (62) |
| ECP | 14 (36) |
| RTX/rapamycin/evero/thali/MTX/AZA/pento | 7/6/2/2/1/1/1 |
| PUVA/TAI/TLI | 4/3/1 |
| 2 or more previous treatments for cGVHD | 37 (95) |
| Mean time from cGVHD to imatinib start, mo (SD) | 29 (28) |
| Imatinib maximal daily posology, mg, n | |
| 100/200/300/400/600 | 9/8/9/13/1 |
| Mean IM treatment duration, mo (SD) | 13 (10) |
| Concomitant treatments for cGVHD, n (%) | |
| Systemic corticosteroids | 33 (85) |
| MMF | 15 (38) |
| CsA | 12 (31) |
| ECP | 6 (15) |
| Rapamycin | 3 (8) |
| 2 or more concomitant treatments | 25 (64) |
| Physician global assessment of skin cGVHD evolution after imatinib start, n (%)* | |
| Complete remission | 1 (2) |
| Improvement | 9 (23) |
| Improvement, then relapse | 2 (5) |
| Stability | 12 (31) |
| Worsening | 15 (39) |
| Overall improvement of skin cGVHD after IM start, n (%) | 12 (31) |
| Corticosteroids tapered, n (%) | 9 (23) |
| Improvement of skin cGVHD, n | 3 |
| Stability of skin cGVHD, n | 5 |
| Worsening of skin cGVHD, n | 1 |
| Corticosteroids discontinued, n (%) | 7 (18) |
| Improvement of skin cGVHD, n | 6 |
| Stability of skin cGVHD, n | 1 |
| Grade 3 or 4 adverse events (WHO), n (%) | 12 (31) |
| Cytopenias | 3 (8) |
| Generalized fluid retention | 7 (18) |
| Impaired consciousness | 2 (5) |
| Outcome at the last follow-up, dead/alive, n | 6/33 |
| Mean follow-up after imatinib start, mo (SD) | 18 (12) |
| . | Values . |
|---|---|
| Sex ratio, male/female, n | 31/8 |
| Mean age, y (range) | 42 (5-70) |
| Diagnosis, n | |
| AML/ALL | 10/8 |
| MM/CML | 7/4 |
| Other MPS/MDS | 3/2 |
| HD/NHL | 2/3 |
| Type of transplantation, sibling/MUD, n | 23/16 |
| Stem cell source, PBSC/BM, n | 32/7 |
| Conditioning, MA/NMA/RIC, n | 27/1/11 |
| GVHD prophylaxis, n | |
| MTX + CsA/MMF + CsA/CsA | 27/11/1 |
| Acute GVHD target organs, n | |
| Skin/gut/both/none | 26/5/6/2 |
| cGVHD target sites, n (%) | |
| Skin (fibrotic features) | 39 (100) |
| Eye and/or mouth mucosa | 32 (82) |
| Lung (bronchiolitis obliterans) | 18 (46) |
| Liver | 9 (23) |
| Digestive tract | 6 (15) |
| 2 or more target sites | 25 (64) |
| cGVHD skin scoring, n (%) | |
| Grade 3 (> 50% BSA OR deep sclerotic features OR ulcerations OR inability to move) | 33 (85) |
| Grade 2 (< 50% BSA and/or superficial sclerotic features only) | 6 (15) |
| Previous treatments for cGVHD, n (%) | |
| Systemic corticosteroids | 39 (100) |
| MMF | 30 (77) |
| CsA | 24 (62) |
| ECP | 14 (36) |
| RTX/rapamycin/evero/thali/MTX/AZA/pento | 7/6/2/2/1/1/1 |
| PUVA/TAI/TLI | 4/3/1 |
| 2 or more previous treatments for cGVHD | 37 (95) |
| Mean time from cGVHD to imatinib start, mo (SD) | 29 (28) |
| Imatinib maximal daily posology, mg, n | |
| 100/200/300/400/600 | 9/8/9/13/1 |
| Mean IM treatment duration, mo (SD) | 13 (10) |
| Concomitant treatments for cGVHD, n (%) | |
| Systemic corticosteroids | 33 (85) |
| MMF | 15 (38) |
| CsA | 12 (31) |
| ECP | 6 (15) |
| Rapamycin | 3 (8) |
| 2 or more concomitant treatments | 25 (64) |
| Physician global assessment of skin cGVHD evolution after imatinib start, n (%)* | |
| Complete remission | 1 (2) |
| Improvement | 9 (23) |
| Improvement, then relapse | 2 (5) |
| Stability | 12 (31) |
| Worsening | 15 (39) |
| Overall improvement of skin cGVHD after IM start, n (%) | 12 (31) |
| Corticosteroids tapered, n (%) | 9 (23) |
| Improvement of skin cGVHD, n | 3 |
| Stability of skin cGVHD, n | 5 |
| Worsening of skin cGVHD, n | 1 |
| Corticosteroids discontinued, n (%) | 7 (18) |
| Improvement of skin cGVHD, n | 6 |
| Stability of skin cGVHD, n | 1 |
| Grade 3 or 4 adverse events (WHO), n (%) | 12 (31) |
| Cytopenias | 3 (8) |
| Generalized fluid retention | 7 (18) |
| Impaired consciousness | 2 (5) |
| Outcome at the last follow-up, dead/alive, n | 6/33 |
| Mean follow-up after imatinib start, mo (SD) | 18 (12) |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; AZA, azathioprin; BSA, body surface area; CML, chronic myelogenous leukemia; CsA, cyclosporin A; ECP, extracorporeal photopheresis; evero, everolimus; HD, Hodgkin disease; MA, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; MPS, myeloproliferative syndrome; MTX, methotrexate; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; NMA, nonmyeloablative conditioning; PBSCs, peripheral blood stem cells; pento, pentostatin; PUVA, psoralen + UVA therapy; RIC, reduced-intensity conditioning; RTX, rituximab; Sib, sibling; tacro, tacrolimus; TAI, thoracoabominal irradiation; thali, thalidomide; TLI, total lymphoid irradiation; and WHO, World Health Organization.
At the time of imatinib discontinuation or at the last follow-up if imatinib treatment was not discontinued.